A Phase I report of paclitaxel dose escalation combined with a fixed dose of carboplatin in the treatment of head and neck carcinoma
β Scribed by Frank R. Dunphy; James H. Boyd; Han J. Kim; Cherie H. Dunphy; Bruce R. Harrison; Teresa L. Dunleavy; Jack J. Rodriguez; Erin M. McDonough; Jeffrey R. Minster; Jack G. Hilton
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 151 KB
- Volume
- 79
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
β¦ Synopsis
Thirty-six patients with untreated Stage III/IV head and neck carcinoma were treated and were evaluable for toxicity. All patients had lesions that were
π SIMILAR VOLUMES
## BACKGROUND. Paclitaxel, an effective chemotherapeutic agent in the management of breast carcinoma, may have activity in women whose disease has recurred after high dose chemotherapy. With this is mind the authors explored the addition of a 120-hour continuous infusion of paclitaxel to a previou
## BACKGROUND. Cytarabine is an essential drug for inducing remission of acute myelogenous leukemia, and it is also one the most effective drugs used as salvage therapy for patients with all types of relapsed acute leukemia. Nevertheless, there is considerable room for improvement in the treatment